- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05995522
Effect of Vitamin K2 Over Osteocalcin, Leptin, Cytokines, and Cardiovascular Risk in Young Adults With Overweight and Obesity
Effect of Vitamin K2 Supplementation and Its Association With Osteocalcin Serum Levels, Leptin, Th1/Th2 Cytokine Profile, and Cardiovascular Risk in Young Mexican Adults With Overweight and Obesity
The goal of this clinical trial is to compare de effect of vitamin K2 in young adults with overweight or obesity. The main questions to answer are:
What is the effect of Vitamin K2 supplementation on methylation, serum concentration of ucOC, cOC, Gas6, leptin, inflammatory markers, cardiometabolic risk factors, and cardiovascular risk in overweight or obese young adults? Participants will be assigned to one of two intervention groups where they will consume Vitamin K2 100 µg per day or cornstarch 500 mg per day for 90 days.
If there is a comparison group: Investigators will compare the supplementation group (Vitamin K2) with the placebo group (cornstarch) to see if vitamin K2 supplementation modifies methylation, increases serum vitamin K, osteocalcin, growth arrest-specific 6 protein serum concentration, decreases serum leptin concentration, inflammatory markers and reduces cardiometabolic risk factors and cardiovascular risk.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Overview To meet the objectives of the project, two groups will be compared, one that will be supplemented with vitamin K and another of patients who will receive corn starch as a placebo. Patients are going to have a follow up during 3 months with periodic evaluations every 30 days.
This is a double-blind study, it is achieved by maintaining similarities in appearance, taste and smell between the treatments that will be delivered in the same vials, with same number of pills and identical in shape, color and consistency for each study group.
Patient recruitment will take place by disseminating information through physical and social media, once potential participants have been identified, they will be contacted and informed about the project, and if they decide to participate in the study, they will be asked to sign the informed consent.
Simple randomization will be performed using R software to assign participants to one of the study groups. A clinical history, anthropometric measurements and blood sampling shall be applied.
Nutritional recommendations based on the position of the Academy of Nutrition and Dietetics for the treatment of overweight and obesity and the healthy eating plate of Harvard University will be given. An appointment is to be scheduled every 30 days in order to provide the supplementation and follow-up. At the end, the pertinent statistical analyzes will be carried out.
Notification of adverse effects will be made in each of the sessions, in addition to this the participants will have the contact of the researchers to notify any anomaly.
Sample's size calculation
The sample size was calculated using the statistical formula for the comparison of two means. This estimate was made using the following formula:
n=2(Zα+Z[1-β]2xSD2/d2
Where:
n= sample size required in each group SD= standard deviation of the effect Zα: to the value of Z for a confidence level of 95% Z[1-β}: to the value of Z for a statistical power of 80% D= effect size A total of 19.72 patients per group were obtained. Considering a 20% loss, 24 patients are needed per study group.
Ethical considerations The study was approved by the Biosafety committee, research ethics committee and research committee of the University Center for Health Sciences, University of Guadalajara: CI-00421. The committees of the University have the authority to monitor and audit the study at any of its stages once it has been approved.
Objetives General objective Evaluate the effect of vitamin K2 supplementation on methylation, the serum concentration of total vitamin K, osteocalcin, growth arrest-specific 6 protein, leptin, inflammatory markers, cardiometabolic risk factors and cardiovascular risk in young Mexican adults with overweight or obesity.
Specific objectives
- Compare the baseline variables between groups.
- Compare the variable changes across the time within groups
- Compare the variable changes across the time between groups
Statistical analysis The Shapiro-Wilk normality test is performed to determine whether the analysis will require parametric or non-parametric tests. Qualitative variables will be expressed as frequencies and percentages, while quantitative variables will be expressed as mean and standard deviation in parametric data or medians and ranges in non-parametric data.
Specific objective 1 Statistical technique T-student for independent samples if it has a normal distribution or by U-Mann Whitney for independent samples if it does not have a normal distribution
Specific objective 2 Variables with two measures Statistical technique T-student for paired samples if it has a normal distribution or the Wilcoxon signed-rank test if it does not have a normal distribution
Variables with more than two measures Statistical technique Repeated measures ANOVA if it has a normal distribution or the Friedman Test if it does not have a normal distribution
Specific objective 3 Statistical technique The effect size of the groups is compared with T-student for independent samples if it has a normal distribution or by U-Mann Whitney for independent samples if it does not have a normal distribution
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Andrés López Quintero, PhD
- Phone Number: 34294 33 1058 5200
- Email: andres.lopezq@academicos.udg.mx
Study Contact Backup
- Name: Edgar A Rivera León, PhD
- Phone Number: 56928 (378) 782 8033
- Email: edgar.rleon@academicos.udg.mx
Study Locations
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44340
- University of Guadalajara
-
Contact:
- Andrés López Quintero, PhD
- Phone Number: 34294 33 1058 5200
- Email: andres.lopezq@academicos.udg.mx
-
Contact:
- Edgar A Rivera León, PhD
- Phone Number: 56928 (378) 782 8033
- Email: edgar.rleon@academicos.udg.mx
-
Principal Investigator:
- Andrés López Quintero, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Body Mass Index greater than 25 kg/m2 and less than 40 kg/m2
- That they agree to participate in the study voluntarily and informed and sign the informed consent
Exclusion Criteria:
- People with self-reported diagnosis of chronic kidney, gastrointestinal or systemic disease
- Use of bile acid sequestrants drugs, insulin, glucocorticoids, contraceptives, bisphosphonates, thiazides, levetiracetam, thiazolidinediones, anticoagulants or estrogenic drugs and vitamin D, vitamin K, vitamin A, vitamin E, omegas or calcium supplements
- Patients who are on a hypocaloric or low-fat diet
- Self-reported pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Supplementation arm
Vitamin K2
|
100 µg per day for 90 days
Other Names:
|
Placebo Comparator: Placebo arm
Cornstarch
|
500 mg per day for 90 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Osteocalcin serum concentration
Time Frame: Baseline and after 90 days of intervention
|
ng/dL
|
Baseline and after 90 days of intervention
|
Vitamin K serum concentration
Time Frame: Baseline and after 90 days of intervention
|
ng/dL
|
Baseline and after 90 days of intervention
|
Leptin serum concentration
Time Frame: Baseline and after 90 days of intervention
|
ng/dL
|
Baseline and after 90 days of intervention
|
Tumour Necrosis Factor alpha serum concentration
Time Frame: Baseline and after 90 days of intervention
|
pg/mL
|
Baseline and after 90 days of intervention
|
Interleukin-1 Beta serum concentration
Time Frame: Baseline and after 90 days of intervention
|
pg/mL
|
Baseline and after 90 days of intervention
|
Interleukin-6 serum concentration
Time Frame: Baseline and after 90 days of intervention
|
pg/mL
|
Baseline and after 90 days of intervention
|
Interleukin-4 serum concentration
Time Frame: Baseline and after 90 days of intervention
|
pg/mL
|
Baseline and after 90 days of intervention
|
Interleukin-10 serum concentration
Time Frame: Baseline and after 90 days of intervention
|
pg/mL
|
Baseline and after 90 days of intervention
|
Cardiovascular risk
Time Frame: Baseline, after 30, 60 and 90 days of intervention
|
percentage
|
Baseline, after 30, 60 and 90 days of intervention
|
LEP gene methylation
Time Frame: Baseline and after 90 days of intervention
|
Methylated or unmethylated
|
Baseline and after 90 days of intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Growth arrest-specific 6 protein serum concentration
Time Frame: Baseline and after 90 days of intervention
|
ng/ml
|
Baseline and after 90 days of intervention
|
Global methylation
Time Frame: Baseline and after 90 days of intervention
|
percentage
|
Baseline and after 90 days of intervention
|
Atherogenic indices
Time Frame: Baseline and after 90 days of intervention
|
Value
|
Baseline and after 90 days of intervention
|
Triglycerides serum concentration
Time Frame: Baseline and after 90 days of intervention
|
mg/dL
|
Baseline and after 90 days of intervention
|
Total cholesterol serum concentration
Time Frame: Baseline and after 90 days of intervention
|
mg/dL
|
Baseline and after 90 days of intervention
|
HDL cholesterol serum concentration
Time Frame: Baseline and after 90 days of intervention
|
mg/dL
|
Baseline and after 90 days of intervention
|
LDL cholesterol serum concentration
Time Frame: Baseline and after 90 days of intervention
|
mg/dL
|
Baseline and after 90 days of intervention
|
VLDL cholesterol serum concentration
Time Frame: Baseline and after 90 days of intervention
|
mg/dL
|
Baseline and after 90 days of intervention
|
Glucose serum concentration
Time Frame: Baseline and after 90 days of intervention
|
mg/dL
|
Baseline and after 90 days of intervention
|
Blood pressure
Time Frame: Baseline, after 30, 60 and 90 days of intervention
|
mmHg
|
Baseline, after 30, 60 and 90 days of intervention
|
Insulin serum concentration
Time Frame: Baseline and after 90 days of intervention
|
µIU/ml
|
Baseline and after 90 days of intervention
|
Weight
Time Frame: Baseline, after 30, 60 and 90 days of intervention
|
kg
|
Baseline, after 30, 60 and 90 days of intervention
|
Body mass index
Time Frame: Baseline, after 30, 60 and 90 days of intervention
|
kg/m2
|
Baseline, after 30, 60 and 90 days of intervention
|
Waist circumference
Time Frame: Baseline, after 30, 60 and 90 days of intervention
|
cm
|
Baseline, after 30, 60 and 90 days of intervention
|
Hip circumference
Time Frame: Baseline, after 30, 60 and 90 days of intervention
|
cm
|
Baseline, after 30, 60 and 90 days of intervention
|
Fat mass
Time Frame: Baseline, after 30, 60 and 90 days of intervention
|
kg
|
Baseline, after 30, 60 and 90 days of intervention
|
% fat
Time Frame: Baseline, after 30, 60 and 90 days of intervention
|
percentage
|
Baseline, after 30, 60 and 90 days of intervention
|
Lean mass
Time Frame: Baseline, after 30, 60 and 90 days of intervention
|
kg
|
Baseline, after 30, 60 and 90 days of intervention
|
Estimated energy consumption
Time Frame: Baseline, after 30, 60 and 90 days of intervention
|
kcal/day
|
Baseline, after 30, 60 and 90 days of intervention
|
Estimated protein consumption
Time Frame: Baseline, after 30, 60 and 90 days of intervention
|
grams/day
|
Baseline, after 30, 60 and 90 days of intervention
|
Estimated carbohydrates consumption
Time Frame: Baseline, after 30, 60 and 90 days of intervention
|
grams/day
|
Baseline, after 30, 60 and 90 days of intervention
|
Estimated fat consumption
Time Frame: Baseline, after 30, 60 and 90 days of intervention
|
grams/day
|
Baseline, after 30, 60 and 90 days of intervention
|
Estimated vitamin K consumption
Time Frame: Baseline, after 30, 60 and 90 days of intervention
|
μg/day
|
Baseline, after 30, 60 and 90 days of intervention
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Andrés López Quintero, PhD
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CI-00421
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overweight and Obesity
-
University Hospital, LilleNational Research Agency, France; European Union; University of Lille Nord de... and other collaboratorsNot yet recruitingOverweight and Obesity | Overweight, Childhood | Overweight, Infant
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Institut Investigacio Sanitaria Pere VirgiliCompletedObesity, Childhood | Overweight and Obesity | Overweight, ChildhoodSpain
-
Memorial Sloan Kettering Cancer CenterRecruitingObesity | Overweight | Overweight and Obesity | Obese | Overweight or ObesityUnited States
-
Holbaek SygehusUniversity of Copenhagen; University of Florida; University of Minnesota; Hebrew... and other collaboratorsRecruitingChildhood Overweight and ObesityDenmark
-
Universidade do Extremo Sul Catarinense - Unidade...RecruitingObesity | Overweight and Obesity | Obesity; Endocrine | Overweight, Obesity and Other HyperalimentationBrazil
-
Mexican National Institute of Public HealthUNICEFCompleted
-
Universidade do PortoFundação para a Ciência e a Tecnologia; Administração Regional de Saúde do... and other collaboratorsCompletedOverweight and ObesityPortugal
-
University of British ColumbiaTerminatedOverweight and ObesityCanada
-
National Taiwan University HospitalCompleted
Clinical Trials on Vitamin K2
-
Université de SherbrookeSamuel Fortin, SFC pharma and associate professor UQARCompleted
-
Hopital St. Georges, AjaltounOmicron Pharmaceuticals; Nattopharma ASAUnknownAortic Valve DiseaseLebanon
-
Maastricht University Medical CenterVitaKCompleted
-
University of AarhusAxellusUnknownMetabolic Bone DisorderDenmark
-
Ain Shams UniversityUnknownEnd Stage Renal DiseaseEgypt
-
Ankara City Hospital BilkentRecruitingPerineal InjuryTurkey
-
Augusta UniversityYale University; University of Alabama at Birmingham; Tufts UniversityUnknownObesity | Diabetes | Insulin Resistance | Dyslipidemia | Insulin Sensitivity | PrediabetesUnited States
-
Chinese University of Hong KongRecruiting
-
Augusta UniversityUnknownHyperglycemia | Cardiovascular Diseases | Obesity | Insulin Resistance | Hyperlipidemia | Nutritional and Metabolic Diseases | Obesity in DiabetesUnited States